Just because a critical failure hasn’t happened yet doesn’t mean it won’t happen in the future. The question becomes: If it ...

As global regulators rethink tobacco control strategies, the U.S. FDA’s move toward a “chain of risk” framework has sparked fresh debate on harm reduction. To understand its implications for India, ...

Background The annual births in our hospital (a regional perinatal centre for the southeastern coastal region) had increased ...

Local infiltration analgesia (LIA) substantially reduces the risk for neuropathic pain (NP) 1 year after total knee arthroplasty (TKA), according to study results published in ACR Open Rheumatology.

Backgrounds/aims: Real-world data are limited regarding long-term outcomes in terms of absolute follow-up values of low-density lipoprotein cholesterol (LDL-C) vs. percentage reductions from baseline ...

Population-based age- and sex-specific percentiles showing 30-year absolute risk estimates for cardiovascular disease, atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) based on ...

Background Recent cardiovascular risk equations from the USA and United Kingdom use routinely collected electronic medical records (EMRs), while current equations used in Australia (AusCVDRisk) have ...

A cardiologist recently suggested that I should consider taking a statin because of my “borderline” cholesterol level. So, I took a dive into the details of statin therapy. I learned that although ...

NEW ORLEANS, LA—A PCSK9 inhibitor used on top of lipid-lowering therapy, including a high-intensity statin, significantly cuts the risk of major adverse cardiovascular events compared with placebo ...

DEAR DR. ROACH: A cardiologist recently suggested that I should consider taking a statin because of my “borderline” cholesterol level. So, I took a dive into the details of statin therapy. I learned ...

Oral semaglutide is now approved to reduce cardiovascular risk in high-risk type 2 diabetes patients, marking a first for oral GLP-1 receptor agonists. The SOUL trial showed a 14% relative risk ...

PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Oct. 17, 2025 /PRNewswire/ -- Novo Nordisk announced today that the US Food and Drug Administration (FDA) has approved Rybelsus ®, the only oral GLP-1 ...